logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Selinexor for advanced or recurrent endometrial cancer – maintenance therapy

< Back

Selinexor for advanced or recurrent endometrial cancer – maintenance therapy

Drugs

Cancer and Palliative Care

May 2020


Selinexor is in clinical development for the endometrial cancer maintenance therapy after combination chemotherapy. Endometrial cancer (uterine cancer) is a common cancer that affects the female reproductive system and starts when cells in the endometrium (the inner lining of the uterus) start to grow out of control. It is more common in women who have been through the menopause. Signs and symptoms of endometrial cancer may include vaginal bleeding after menopause, pelvic pain, loss of appetite, tiredness, and nausea. The exact cause of the disease is not clear, but some factors can increase the risk of developing it. One of the main risk factors for endometrial cancer is higher levels of oestrogen in the body.

Selinexor works by selectively inhibiting nuclear export (SINE) compounds. By blocking exportin 1 (XPO1), selinexor blocks the nuclear export of tumour suppressor, growth regulatory, and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. If licensed, selinexor will offer a maintenance treatment option for endometrial cancer after combination chemotherapy.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts